Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Daniel Barber is President and CEO at Aquestive Therapeutics. OQRO lists 3 transactions filed with the SEC under this name, the latest on Oct 16, 2026, each linked to the official Form 4.
President and CEO
Disclosures on record
3
Companies involved
1
Aquestive TherapeuticsAQST
3 disclosures · Sep 2025 – Oct 2026 · 3 sold
Oct 15, 2026Sold~$106Kdisclosed Oct 16
DetailsOfficial recordSep 26, 2025Sold~$551Kdisclosed Sep 29
DetailsOfficial recordSep 19, 2025Sold~$2.4Kdisclosed Sep 22
DetailsOfficial recordDaniel Barber bought shares on the open market in 2018, 2019 and 2022, and has not bought since 2022. Sales in 2 of the 9 years since 2018.
Daniel Barber reported 3 open-market purchases and 3 sales since 2018; purchases in 3 different years, most recently 2022.
| Year | Bought | Sold |
|---|---|---|
| 2026 | — | $106K1×1 trade |
| 2025 | — | $554K2×2 trades |
| 2022 | $88K1×1 trade | — |
| 2019 | $8K1×1 trade | — |
| 2018 | $8K1×1 trade | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
As of the latest filing on , Daniel Barber reported holding 627,317 shares of Aquestive Therapeutics (AQST), worth about $2.45M at the last close of $4 (Nov 13, 2026). In the last 12 months, Daniel Barber sold $106K in 1 sale.
Aquestive Therapeutics's proxy statement reports total compensation of $3.49M for Daniel Barber for fiscal year 2025, after $4.18M for 2024. The total is the one in the Summary Compensation Table: it counts stock awards at their value on the grant date, so it is not the cash received. Proxy statement filed Apr 24, 2026
| Company | Shares reported | How held | Last close | Value at last close | Reported |
|---|---|---|---|---|---|
| Aquestive Therapeutics AQST | 627,317 | 627K direct | $4 | $2.45M | Oct 15, 2026 |
Is this Daniel Barber’s net worth? No. A Form 4 reports the shares an insider owns in one company after each transaction, directly or through trusts and entities. It says nothing about cash, other investments, property or debt, options not yet exercised are not counted here, and a holding reported some time ago may have changed without a new filing. The value is shares times the last stored close, not a price anyone received. Sources: the filings listed below, each linked to EDGAR. Compare with the biggest insider stakes.
On the latest SEC Form 4, dated Oct 15, 2026, Daniel Barber reported holding 627,317 shares of Aquestive Therapeutics (AQST). At the last close of $4 on Nov 13, 2026, that is about $2.45M. This is the stake disclosed in filings, not a net worth.
In SEC filings of the last 12 months, Daniel Barber reported 1 open-market sale worth $106K, and no open-market purchase. Shares withheld for taxes, gifts and option exercises are not counted in these totals.
Aquestive Therapeutics's proxy statement reports total compensation of $3.49M for Daniel Barber for fiscal year 2025, after $4.18M for 2024. The total is the one in the Summary Compensation Table: it counts stock awards at their value on the grant date, so it is not the cash received.
Daniel Barber bought shares on the open market in 2018, 2019 and 2022, and has not bought since 2022. Sales in 2 of the 9 years since 2018.
In SEC filings since 2018: the latest open-market purchase is from 2022; the latest open-market sale is from 2026.
Aquestive Therapeutics (AQST), from 2018 to 2026: 3 purchases and 3 sales.
Daniel Barber reported 3 open-market purchases and 3 sales here, 2018 to 2026.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.
